General Inception Launches Igniter Europe with the support of leading institutions and venture capital firms
Retrieved on:
Tuesday, April 30, 2024
University, Super-resolution microscopy, Ecosystem, Acceleration, Tech, Innovation system, Computational chemistry, Machine learning, RNA, Partnership, Digital, Research, AAV, Investment, Therapy, Patient, PALO, Inflammation, Tavira, Drug development, Autoimmunity, NK, Biotechnology, ESPCI, KU Leuven, Pharmaceutical industry
PALO ALTO, Calif. and LYON, France, April 29, 2024 /PRNewswire-PRWeb/ -- General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive technology platforms that enable accelerated drug development with data analytics solutions leveraging patients' data and clinical insights early on in the phase of drug development.
Key Points:
- The company works closely with renowned researchers and institutions to facilitate the inception and acceleration of startups.
- The team operates daily on both sides of the Atlantic to streamline the development of breakthrough solutions for the healthcare industry.
- "Igniter Europe's approach in the field of company creation and expansion, in close collaboration with General Inception, is quite original.
- "Our support is based on more than 15 years' experience with the team as deeptech venture capital investors and a shared conviction in the value of their mission.